CUMYL-NBMINACA

CUMYL-NBMINACA is a synthetic cannabinoid that has been identified in illicit products. It is a potent agonist for the CB1 receptor and CB2 receptor. CUMYL-NBMINACA was first identified in Slovenia in 2017 and has since been found in a number of other countries. It is illegal in many jurisdictions, including the United States, where it is a Schedule I controlled substance.

Chemistry

CUMYL-NBMINACA is a member of the indazole-3-carboxamide family of synthetic cannabinoids. It is structurally related to other synthetic cannabinoids such as 5F-CUMYL-PINACA. The chemical formula of CUMYL-NBMINACA is C22H24N4O2.

Pharmacology

CUMYL-NBMINACA is a potent agonist for the CB1 and CB2 receptors. The CB1 receptor is primarily located in the brain and is responsible for the psychoactive effects of cannabinoids. The CB2 receptor is primarily found in the immune system and is involved in immune response and inflammation.

Effects

The effects of CUMYL-NBMINACA are similar to those of other synthetic cannabinoids and include euphoria, relaxation, and altered perception. However, it is significantly more potent than natural cannabinoids such as THC, and this increased potency can lead to more severe adverse effects. These can include anxiety, paranoia, hallucinations, and psychosis. In some cases, use of CUMYL-NBMINACA has been associated with serious health risks, including seizures and death.

Legal status

CUMYL-NBMINACA is illegal in many jurisdictions. In the United States, it is a Schedule I controlled substance, which means it is considered to have a high potential for abuse and no accepted medical use. It is also illegal in many European countries, including Slovenia, where it was first identified.

See also

• Synthetic cannabinoids
• Indazole-3-carboxamide
• CB1 receptor
• CB2 receptor

CUMYL-NBMINACA Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski